Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H24N2O4S.ClH |
| Molecular Weight | 364.888 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O
InChI
InChIKey=OTFDPNXIVHBTKW-UHFFFAOYSA-N
InChI=1S/C15H24N2O4S.ClH/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3;/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18);1H
DescriptionSources: http://db.cbg-meb.nl/Pars/h32520.pdfCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11520476
Sources: http://db.cbg-meb.nl/Pars/h32520.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11520476
Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly. A derivative of benzamide, tiapride is chemically and functionally similar to other benzamide antipsychotics such as sulpiride and amisulpride known for their dopamine antagonist effects. Tiapride is marketed under various trade names and is widely available outside of the United States. The most common trade name for tiapride is Tiapridal, which is used throughout Europe, Russia, as well as parts of South America, the Middle East, and North Africa. It is also sold under different names in Italy (Italprid, Sereprile), Japan (Tialaread, Tiaryl, Tiaprim, Tiaprizal), Chile (Sereprid), Germany (Tiaprid, Tiapridex), and China (Tiapride).
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL339 |
45.8 µM [IC50] | ||
| 11.7 µM [IC50] | |||
Target ID: CHEMBL234 |
180.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Tiacob Approved UseFor the treatment of neuroleptic-induced tardive dyskinesia, mainly oro-bucco-lingual type. Launch Date2005 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation. | 1993 Sep-Oct |
|
| Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal. | 2001 Nov |
|
| [Models of drug treatment in the attention deficit disorder with hyperactivity]. | 2002 Feb |
|
| The treatment of Tourette's syndrome: current opinions. | 2002 Jul |
|
| [Autonomic cardiovascular regulation in patients with tics and Tourette syndrome]. | 2005 |
|
| Tiapride may accelerate lung cancer in older people: a case report. | 2005 Apr |
|
| A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. | 2005 Feb |
|
| [Iatrogenic neurological disorders in old people: a review]. | 2005 Jan |
|
| Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of tiapride. | 2005 Nov-Dec |
|
| Tiapride pre-treatment in acute exposure to paraoxon: comparison of effects of administration at different points-in-time in rats. | 2006 Apr |
|
| [Identification of haloperidol and tiapride in the urine with thin layer chromatography]. | 2006 Mar-Apr |
|
| Impaired cognition and attention in adults: pharmacological management strategies. | 2007 Feb |
|
| [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. | 2007 Mar |
|
| Stability-indicating methods for determination of tiapride in pure form, pharmaceutical preparation, and human plasma. | 2007 Nov-Dec |
|
| Metoclopramide protection of diazinon-induced toxicosis in chickens. | 2007 Sep |
|
| Voluntary motor drive: possible reduction in Tourette syndrome. | 2008 Jun |
|
| Development of membrane selective electrode for determination of the antipsychotic sulpiride in pharmaceuticals and urine. | 2009 |
|
| [Tiapride with the horn of saiga tatarica in the treatment of hemifacial spasm]. | 2009 Aug |
|
| Rapid quantification of levosulpiride in human plasma using RP-HPLC-MS/MS for pharmacokinetic and bioequivalence study. | 2009 Dec |
|
| Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. | 2010 Feb |
|
| Depression, extrapyramidal symptoms, dementia and an unexpected outcome: a case report. | 2010 Feb 2 |
|
| [A control study of aripiprazole and tiapride treatment for tic disorders in children]. | 2010 Jun |
|
| Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. | 2010 Mar |
|
| Presynaptic dopaminergic agonists increased gripping-generated immobility episodes in the myelin-mutant taiep rat. | 2010 Oct 15 |
Patents
Sample Use Guides
Adults should take 100 – 200 mg tiapride three times daily, depending on the severity of the disease and the body weight of the individual . The proposed daily dose for the claimed indication is 300 – 600 mg tiapride.
The effect of treatment may not be apparent until after a period of 4-6 weeks of treatment. Tiapride tablets should preferably be taken with a little liquid after meals.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: Effects of tiapride on hERG channels expressed in Xenopus oocytes and also on delayed rectifier K(+) currents in guinea pig cardiomyocytes were studied.
Tiapride increased the potential for half-maximal activation (V(1/2)) of HERG at 10~300 uM. In guinea pig ventricular myocytes, bath applications of 100 and 500 uM tiapride at 36℃ blocked rapidly activating delayed rectifier K(+) current (I(Kr)) by 40.3% and 70.0%, respectively.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
256-908-4
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL84158
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY | |||
|
DTXSID4045210
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY | |||
|
25N106WEDO
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY | |||
|
100000091110
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY | |||
|
39855
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY | |||
|
51012-33-0
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY | |||
|
m10846
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB04854MIG
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY | |||
|
DBSALT002373
Created by
admin on Fri Dec 15 19:25:37 GMT 2023 , Edited by admin on Fri Dec 15 19:25:37 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
